Zero Candida Announces TSX Venture Exchange Listing Date According to Investing.com

VANCOUVER, BC, November 21, 2024 /PRNewswire/ — Zero Candida Technologies Inc. (“Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on the development and commercial exploitation of several patents and patent applications on devices such as AI smart tampons, designed to treat Candidiasis and transfer medical information via Wi-Fi to doctor, is pleased to announce that its common stock (“Common Stock”) is expected to begin trading on TSX Venture Exchange (the “TSXV”) at the market opening on November 25, 2024.

Zero Candida recently completed a business acquisition Zero Candida Ltd.Israeli private companies (“ZC” and “Acquisition”). Upon completion of the Acquisition, the Company has a total of 19,533,037 Common Shares issued and outstanding. Additional details about the Company and the Acquisition are contained in the Company’s Form 2B TSXV Listing Application, which is available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

About Zero Candida

Zero Candida focuses on the commercial exploitation of several patents and patent applications on devices like AI smart tampons, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapeutic light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device, when used overnight, showed 99.9999% elimination of candidiasis in the vagina within 3 nights.

ZC developed the first prototype of the device in May 2022 and immediately began the first laboratory tests as a “proof of concept”. At September 2023 ZC completed the pre-clinical animal studies and then developed the protype (series 1) and began validation. ZC is currently developing the device design and continuing pre-clinical animal studies. ZC expects to pursue “Fast Track” approval with the FDA as a Class II De Novo device.

At May 2024ZC received a report on pre-clinical safety studies, which showed no abnormal findings in gross pathology and histopathology and no safety concerns regarding ZC’s blue light device.

On behalf of the Board of Directors
Eli Ben HarooshCEO
For more information contact
Mr. Eli Ban-Haroosh at eli@zero-candida.com;
(647) 874-3767

NO SECURITIES REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENTS OF THIS RELEASE. THE TSXV OR REGULATORY SERVICE PROVIDERS (AS THOSE TERMS ARE DEFINED IN TSXV POLICY) DO NOT ACCEPT ANY RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

THIS PRESS RELEASE IS REQUIRED BY APPLICABLE CANADIAN LAW NOT TO BE DISTRIBUTED TO ACE NEWS SERVICE OR FOR DISSEMINATION IN UNITED STATES OF AMERICAAnd it does not constitute an offer to sell or a solicitation of an offer to sell the securities described herein. UNITED STATES OF AMERICATHESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED IN UNITED STATES OF AMERICA THE SECURITIES ACT OF 1993, AS AMENDED, OR THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD IN UNITED STATES OF AMERICA OR ACE People unless registered or exempt from.

FORWARD-LOOKING STATEMENTS

The information set forth in this news release may include forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to the future, not past events. In this context, forward-looking statements often deal with future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that actions or events “may”, “could”, “could”, “must”, or “will” take place or occur, including statements relating to the issuance of securities and the characteristics described herein, the application Company Listing agreement, or the expression other the same, all statements, except statements of historical facts included here including, without limitation, statements regarding securities herein. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or other future events, to differ materially from those results, performance, or future performance indicated or implied by such forward-looking statements. These factors include, among others, the following risks: the need for additional financing; operational risks related to the protection of intellectual property rights, product liability; regulatory risk; enforcement of judgments against foreigners; foreign exchange rate fluctuations; economic, political and military instability Israel;; and additional risks identified in the Listing Application filed in the issuer’s profile on SEDAR+ or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions as of the date the statements are made and the Company undertakes no obligation to update forward-looking statements if those beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned not to provide undue certainty in forward-looking statements.

Logo – https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg